Tanvex Presents Results of TX05 (biosimilar, trastuzumab) in P-III Study for the Treatment of HER2-Positive Early Stage Breast Cancer at ESMO 2021

Shots:

• The P-III study evaluates TX05 (biosimilar, trastuzumab) vs Herceptin in 809 patients with HER2-positive early-stage breast cancer
• The results showed that the proportions of patients that meet pCR criteria for equivalence were highly similar b/w TX05 (48.8%) and TRA (45.3%) cohorts; ORR (84.3%) & (85.0%); CR; PR and stable disease were also highly similar, patients experienced TEAEs (62.4% vs 62.5%), respectively
• Additionally, the therapy was well tolerated & the safety profile was consistent with the known profile of TRA

Click here to­ read full press release/ article | Ref: Centre for Biosimilar | Image: Tanvex Biopharma